These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 26640371)

  • 1. Spotlight on tavaborole for the treatment of onychomycosis.
    Jinna S; Finch J
    Drug Des Devel Ther; 2015; 9():6185-90. PubMed ID: 26640371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults.
    Gupta AK; Daigle D
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):735-42. PubMed ID: 24894552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tavaborole - a treatment for onychomycosis of the toenails.
    Gupta AK; Versteeg SG
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1145-52. PubMed ID: 27347905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis.
    Gupta G; Foley KA; Gupta AK
    Skin Therapy Lett; 2015 Nov; 20(6):6-9. PubMed ID: 27224843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies.
    Elewski BE; Aly R; Baldwin SL; González Soto RF; Rich P; Weisfeld M; Wiltz H; Zane LT; Pollak R
    J Am Acad Dermatol; 2015 Jul; 73(1):62-9. PubMed ID: 25956661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.
    Toledo-Bahena ME; Bucko A; Ocampo-Candiani J; Herz-Ruelas ME; Jones TM; Jarratt MT; Pollak RA; Zane LT
    J Drugs Dermatol; 2014 Sep; 13(9):1124-32. PubMed ID: 25226015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tavaborole topical solution, 5% for the treatment of toenail onychomycosis.
    Zane LT; Plattner J; Chanda S; Coronado D; Merchant T; Alley MR; Gupta AK
    Drugs Today (Barc); 2015 Oct; 51(10):599-607. PubMed ID: 26583302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential role of tavaborole for the treatment of onychomycosis.
    Gupta AK; Daigle D
    Future Microbiol; 2014; 9(11):1243-50. PubMed ID: 25437186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tavaborole for the treatment of onychomycosis.
    Elewski BE; Tosti A
    Expert Opin Pharmacother; 2014 Jul; 15(10):1439-48. PubMed ID: 24856836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tavaborole 5% solution for onychomycosis.
    Gupta AK; Daigle D; Abramovits W
    Skinmed; 2015; 13(1):55-8. PubMed ID: 25842473
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults: a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies.
    Gupta AK; Hall S; Zane LT; Lipner SR; Rich P
    J Dermatolog Treat; 2018 Feb; 29(1):44-48. PubMed ID: 28521541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tavaborole: first global approval.
    Markham A
    Drugs; 2014 Sep; 74(13):1555-8. PubMed ID: 25118637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efinaconazole and Tavaborole.
    Poulakos M; Grace Y; Machin JD; Dorval E
    J Pharm Pract; 2017 Apr; 30(2):245-255. PubMed ID: 26873506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical Tavaborole in the Treatment of Onychomycosis Complicated by Dermatophytoma: A Post-hoc Assessment of Phase II Subjects.
    Aly R; Winter T; Hall S; Vlahovic T
    J Drugs Dermatol; 2018 Mar; 17(3):347-354. PubMed ID: 29537453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
    Rosen T; Stein Gold LF
    Semin Cutan Med Surg; 2016 Mar; 35(3 Suppl 3):S51-5. PubMed ID: 27074700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.
    Aly R; Gupta AK; Winter T; Zane LT; Vlahovic T
    J Drugs Dermatol; 2017 Oct; 16(10):1016-1021. PubMed ID: 29036255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tavaborole 5% Topical Solution for the Treatment of Toenail Onychomycosis in Pediatric Patients: Results from a Phase 4 Open-Label Study.
    Rich P; Spellman M; Purohit V; Zang C; Crook TJ
    J Drugs Dermatol; 2019 Feb; 18(2):190-195. PubMed ID: 30811142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Nail Penetration and Antifungal Activity of Tavaborole, a Boron-Based Pharmaceutical.
    Coronado D; Merchant T; Chanda S; Zane LT
    J Drugs Dermatol; 2015 Jun; 14(6):609-14. PubMed ID: 26091387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tavaborole topical solution (Kerydin) for onychomycosis.
    Med Lett Drugs Ther; 2015 Mar; 57(1463):35-6. PubMed ID: 25719999
    [No Abstract]   [Full Text] [Related]  

  • 20. Planimetric Post-hoc Analysis of Women With Onychomycosis from Tavaborole 5% Phase III Studies: Evidence of Greater Improvements in Patients With >50% Baseline Infection.
    Pariser DM; Wendelken ME; Rycerz AM; Gellings Lowe N; Yost JM; Lipner SR
    J Drugs Dermatol; 2018 Feb; 17(2):168-172. PubMed ID: 29462224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.